Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal

Immatics is hitting the gas pedal on another Bristol Myers Squibb deal as the biotech-Big Pharma pair also level up their 2019 pact, originally inked with Celgene.

While the German-Houston biotech is still in its early-stage clinical development days, Bristol Myers likes what it has seen and wants to dive…